Risk of metachronous neoplasia in early-onset colorectal cancer: meta-analysis
BJS Open · 2024
DOI: 10.1093/bjsopen/zrae092 ↗Kurz gefasst
Metaanalyse in der Zeitschrift BJS Open, 2024. Verfasst von Gianluca Pellino und 6 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Surgery, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona UAB, Barcelona, Spain. Hauptthemen laut MEDLINE: Age of Onset, Colorectal Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Microsatellite Instability. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metachronous colorectal cancer refers to patients developing a second colorectal neoplasia diagnosed at least 6 months after the initial cancer diagnosis, excluding recurrence. The aim of this systematic review is to assess the incidence of metachronous colorectal cancer in early-onset colorectal cancer (defined as age at diagnosis of less than 50 years) and to identify risk factors.
Methods
This is a systematic review and meta-analysis performed following the PRISMA statement and registered on PROSPERO. The literature search was conducted in PubMed and Embase. Only studies involving patients with early-onset colorectal cancer (less than 50 years old) providing data on metachronous colorectal cancer were included in the analysis. The primary endpoint was the risk of metachronous colorectal cancer in patients with early-onset colorectal cancer. Secondary endpoints were association with Lynch syndrome, family history and microsatellite instability.
Results
Sixteen studies met the inclusion criteria. The incidence of metachronous colorectal cancer was 2.6% (95% c.i. 2.287–3.007). The risk of developing metachronous colorectal cancer in early-onset colorectal cancer versus non-early-onset colorectal cancer patients demonstrated an OR of 0.93 (95% c.i. 0.760–1.141). The incidence of metachronous colorectal cancer in patients with Lynch syndrome was 18.43% (95% c.i. 15.396–21.780), and in patients with family history 10.52% (95% c.i. 5.555–17.659). The proportion of metachronous colorectal cancer tumours in the microsatellite instability population was 19.7% (95% c.i. 13.583–27.2422).
Conclusion
The risk of metachronous colorectal cancer in patients with early-onset colorectal cancer is comparable to those with advanced age, but it is higher in patients with Lynch syndrome, family history and microsatellite instability. This meta-analysis demonstrates the need to personalize the management of patients with early-onset colorectal cancer according to their risk factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Colorectal Surgery, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona UAB, Barcelona, Spain.
- Colorectal Surgery, Department of Advanced Medical and Surgical Sciences, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy.
- Molecular Medicine, Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.
- Department of Surgery, Vithas Arturo Soria University Hospital, Madrid, Spain.
ORCID-Profile: Gianluca Pellino, Jose Perea
Zitieren
APA
Pellino, G., Fuschillo, G., González-Sarmiento, R., Martí-Gallostra, M., Selvaggi, F., Espín-Basany, E., & Perea, J. (2024). Risk of metachronous neoplasia in early-onset colorectal cancer: meta-analysis. BJS Open. https://doi.org/10.1093/bjsopen/zrae092
Vancouver
Pellino G, Fuschillo G, González-Sarmiento R, Martí-Gallostra M, Selvaggi F, Espín-Basany E, et al. Risk of metachronous neoplasia in early-onset colorectal cancer: meta-analysis. BJS Open. 2024. doi:10.1093/bjsopen/zrae092
BibTeX
@article{Pellino2024,
author = {Pellino, Gianluca and Fuschillo, Giacomo and González-Sarmiento, Rogelio and Martí-Gallostra, Marc and Selvaggi, Francesco and Espín-Basany, Eloy and Perea, Jose},
title = {Risk of metachronous neoplasia in early-onset colorectal cancer: meta-analysis},
journal = {BJS Open},
year = {2024},
doi = {10.1093/bjsopen/zrae092}
}
EUVIMED